Sensitization of neuroblastoma cells for trail-induced apoptosis by nf-Kb inhibition

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1301-1311

  Ammann, Johannes U ^a   Haag, Christian ^a   Kasperczyk, Hubert ^a   Debatin, Klaus Michael ^a   Fulda, Simon ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; Neuroblastoma; NF kB; TRAIL

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; CASPASE; CISPLATIN; CYTOCHROME C; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; I KAPPA B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEIN MCL 1; REPRESSOR PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; HAIRPIN RIBOZYME; LUCIFERASE; RIBOZYME;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL PROTECTION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; RNA INTERFERENCE; SENSITIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; CULTURE TECHNIQUE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; PATHOLOGY; PHYSIOLOGY; RETROVIRUS;

APOPTOSIS; CELL CULTURE TECHNIQUES; CELL DEATH; CYTOCHROMES C; HUMANS; LUCIFERASES; NEUROBLASTOMA; NF-KAPPA B; RETROVIRIDAE; RNA INTERFERENCE; RNA, CATALYTIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 60549092351     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24068     Document Type: Article

References (48)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma, Nat Rev Cancer 2003;3:203-16.
2. Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000:59:1261-77.
3. Hengartner MO, The biochemistry of apoptosis. Nature 2000:407: 770-6.
4. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-811.
5. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily, Nat Rev Cancer 2002;2:420-30.
6. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Van-denabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004;23:2861-74.
7. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane perme-abilization in cell death. Physiol Rev 2007;87:99-163,
8. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoyreceptors. Cell Death Differ 2003; 10:66-75.
9. Duiker EW, Mom CH, de Jong S, Wiilemse FH, Gietema JA, van der Zee AG, de Vries EG. The clinical trail of TRAIL. Eur J Cancer 2006;42:2233-40.
10. Fulda S, Debatin KM. Modulation of TRAIL signaling for cancer therapy. Vitam Horm 2004;67:275-90,
11. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
12. Hayden MS. Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18:2195-224.
13. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C, Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86. and a set of antiapoptotic genes in Hodgkin/Reed-Stemberg cells. Blood 2001;97:2798-807.
14. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells, Clin Cancer Res 1999;5:119-27.
15. Karin M, Yamamoto Y, Wang QM, The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004:3:17-26.
16. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM, Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998:91:4624-31.
17. Perkins ND. Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 2006;13:759-72.
18. Kasperczyk H, La Feria-Bruhl K, Westhoff MA, Behrend L, Zwacka RM, Debatin KM, Fulda S. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene 2005;24:6945-56.
19. Denk A, Goebeler M, Schmid S, Berberich I, Ritz O, Lindemann D, Ludwig S, Wirth T, Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem 2001:276: 28451-8.
20. Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007;26:248-57.
21. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer PH, Peter ME, Debatin KM. Betulinic acid triggers CD95 (APO-l/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997;57:4956- 64.
22. Mohr A, Zwacka RM, Debatin KM, Stahnke K. A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ 2004:11 :l153-4.
23. Fulda S, Debatin KM, Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004;64:337-46.
24. Kim B, Feidman EL, Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem 2002:277:27393-400.
25. Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R, Response to paclitaxel, topote-can, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study, J Clin Oncol 2004;22;4119-26.
26. Trauzold A, Wermami H, Arlt A, Sehutze S, Schafer H, Oestern S, Roder C, Ungefroren H, Lampe E, Heinrich M, Walczak H, Kaithoff H. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001; 20:4258-69.
27. Campbell KJ, O'shea JM, Perkins ND. Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors. BMC Cancer 2006;6:101.
28. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, lotzova VS, Clarke W, Stmad J, Qiu Y, Zusi FC. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 2003;278:1450-6.
29. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003;22:8961-82.
30. Campbell KJ, Witty JM, Rocha S, Perkins ND. Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation. Cancer Res 2006;66:929-35.
31. Piret B, Piette J. Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. Nucleic Acids Res 1996;24:4242-8.
32. Weaver KD, Yeyeodu S, Cusack JC, Jr. Baldwin AS, Jr, Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 2003 ;61:187-96.
33. Wang CY, Mayo MW, Baldwin AS, Jr. T.NF- and cancer therapy-induced apoptosis: potentiation bv inhibition of NF-kappaB. Science 1996;274:784-7.
34. Bentires-Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP, Bours V. Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 1999;59:811-5.
35. Hewson QD, Lovat PE, Corazzari M, Catterall JB, Redfern CP. The NF-kappaB pathway mediates fenretinide-induced apoptosis in SH-SY5Y neuroblastoma cells. Apoptosis 2005;10:493-8.
36. Bian X, Giordano TD, Lin HJ, Solomon G, Castle VP, Opipari AW, Jr. Chemotherapy-induced apoptosis of S-type neuroblastoma cells requires caspase-9 and is augmented by CD95/Fas stimulation. J Biol Chem 2004;279:4663-9.
37. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapop-totic gene expression bv RelA(p65) NF-kappa B. Mol Cell 2004; 13:853-65.
38. Kim HS, Chang I, Kim JY, Choi KH, Lee MS. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis. Cancer Res 2005:65:6111-9.
39. Ehrhardt H, Fulda S, Sehmid 1, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003;22:3842-52.
40. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22:8543-67.
41. Ricci MS, Kim S-H, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007; 12:66-80.
42. Clohessy JG, Zhuang J, de Boer J, Gil-Gomez G, Brady HJM. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 2006:281:5750-9.
43. Han J, Goldstein LA, Gastman BR, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 2006;281:10153-63.
44. Meng XW, Lee S-H, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL- induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007:282:29831-6.
45. Henson ES, Gibson EM, Villanueva J, Bristow NA, Haney N, Gibson SB. Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated bv EGF/ErbBl signaling pathway. J Cell Biochera 2003;89:1177-92.
46. Kim S-H, Ricci MS, El-Deiry WS. Mcl-1: a gateway to TRAIL sensitization. Cancer Res 2008;68:2062-4.
47. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med 2001 ;79:428-36.
48. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-77.